NCT01262898 - Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2011

Primary Completion Date

February 26, 2013

Study Completion Date

February 26, 2013

Conditions

Gastroparesis

Interventions

DRUG

GSK962040 (5 mg tablet)

5 mg tablet

DRUG

GSK962040 (25 mg tablet)

25 mg tablet

DRUG

GSK962040 (125 mg tablet)

125 mg tablet

DRUG

Placebo

matching placebo tablet

Trial Locations (22)

1090

GSK Investigational Site, Brussels

2031

GSK Investigational Site, Randwick

3000

GSK Investigational Site, Leuven

11023

GSK Investigational Site, Great Neck

20815

GSK Investigational Site, Chevy Chase

23294

GSK Investigational Site, Richmond

37421

GSK Investigational Site, Chattanooga

46202

GSK Investigational Site, Indianapolis

53215

GSK Investigational Site, Milwaukee

78258

GSK Investigational Site, San Antonio

94520

GSK Investigational Site, Concord

02114

GSK Investigational Site, Boston

T2N 4N1

GSK Investigational Site, Calgary

T6G 2E1

GSK Investigational Site, Edmonton

L4J 8L7

GSK Investigational Site, Thornhill

M4G 3E8

GSK Investigational Site, Toronto

SE-751 85

GSK Investigational Site, Uppsala

CB2 2GG

GSK Investigational Site, Cambridge

DD1 9SY

GSK Investigational Site, Dundee

W12 0HS

GSK Investigational Site, London

W1G 6AD

GSK Investigational Site, London

M6 8HD

GSK Investigational Site, Salford